Join us in this lite bite episode as Dr. Aravind Asokan, Duke University, explores cutting-edge technologies revolutionizing advanced therapies, including CRISPR, mRNA, viral vectors, and cell therapies. He shares key lessons from past challenges, discusses scalability, product quality, and how integrating various therapeutic approaches is shaping the future of disease treatment.
This episode covers exciting advancements in AAV with CRISPR, CAR T cell therapy, circular RNA, and virus-like particles (VLPs). 

Show notes
Asokan A, et al. ‘An evolved AAV variant enables efficient genetic engineering of murine T cells’. Cell. 2023 Jan 19;186(2):446-460. <a href="https://doi.org/10.1016/j.cell.2022.12.022 " target="_blank" rel="ugc noopener noreferrer">https://doi.org/10.1016/j.cell.2022.12.022 </a>

Podurama

Home

Trending

Personal

Your Podcasts

New Episodes

My Files

Favourite Episodes

Tags (Folders)

Recently Played

Bookmarks

Followed Playlists

95. Modality convergence in advanced therapies

Discovery Matters

AI Chapters

AI Insights

Reviews